Skip to main content
SpringerLink
Log in

Gefitinib/osimertinib

Development of gefitinib and osimertinib resistance and transformation of the lung adenocarcinoma to small cell lung cancer: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Liam C, et al. Case series of small cell lung cancer transformation as resistance mechanism to epidermal growth factor receptor-tyrosine kinase inhibitor. Journal of Thoracic Oncology 12 (Suppl. 2): S2342 abstr. P3.15-014, No. 11, Nov 2017 [abstract] - Malaysia

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gefitinib/osimertinib. Reactions Weekly 1695, 193 (2018). https://doi.org/10.1007/s40278-018-44020-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-44020-2

Search

Navigation